Tekmira Pharmaceuticals (TKMR) Acquires Worldwide Exclusive License to Novel RNAi Platform
Tweet
Share
E-mailGet Alerts TKMR Hot Sheet
Join SI Premium – FREE
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR) has obtained an exclusive, worldwide license to a novel and proprietary RNAi technology called MV-RNA (multivalent RNA) from Halo-Bio RNAi Therapeutics, Inc. (Halo-Bio). The exclusive license and collaboration agreement provides for the companies to work together to design and develop MV-RNA molecules to gene targets of interest to Tekmira and to combine MV-RNA molecules with Tekmira's lipid nanoparticle (LNP) technology to develop therapeutic products.
Under the license agreement, Tekmira has received exclusive worldwide rights to Halo-Bio's MV-RNA technology for the development of therapeutic products. Tekmira and Halo-Bio will continue an ongoing research collaboration to design and optimize MV-RNA molecules against gene targets of interest. Financial terms of the license agreement were not disclosed.
Under the license agreement, Tekmira has received exclusive worldwide rights to Halo-Bio's MV-RNA technology for the development of therapeutic products. Tekmira and Halo-Bio will continue an ongoing research collaboration to design and optimize MV-RNA molecules against gene targets of interest. Financial terms of the license agreement were not disclosed.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
